ID17156A - Zat-zat anti koagulan yang berguna dalam pengobatan trombosis - Google Patents

Zat-zat anti koagulan yang berguna dalam pengobatan trombosis

Info

Publication number
ID17156A
ID17156A IDP970140A ID970140A ID17156A ID 17156 A ID17156 A ID 17156A ID P970140 A IDP970140 A ID P970140A ID 970140 A ID970140 A ID 970140A ID 17156 A ID17156 A ID 17156A
Authority
ID
Indonesia
Prior art keywords
coagulan
trombosis
treatment
substance use
substance
Prior art date
Application number
IDP970140A
Other languages
English (en)
Inventor
Michael Neal Blackburn
Andrew John Nichols
Giora Zeev Feuerstein
Arunbhai Haribhai Patel
Mitchell Stuart Gross
Daniel Robert Sylverter
Original Assignee
Smithkline Beecham Corp
Univ Vermont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Univ Vermont filed Critical Smithkline Beecham Corp
Publication of ID17156A publication Critical patent/ID17156A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IDP970140A 1996-01-17 1997-01-17 Zat-zat anti koagulan yang berguna dalam pengobatan trombosis ID17156A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1010896P 1996-01-17 1996-01-17
US2911996P 1996-10-24 1996-10-24

Publications (1)

Publication Number Publication Date
ID17156A true ID17156A (id) 1997-12-04

Family

ID=26680794

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP970140A ID17156A (id) 1996-01-17 1997-01-17 Zat-zat anti koagulan yang berguna dalam pengobatan trombosis

Country Status (25)

Country Link
US (5) US6005091A (id)
EP (2) EP1007089B1 (id)
JP (2) JP2000503210A (id)
KR (1) KR100553629B1 (id)
CN (1) CN1213312A (id)
AR (1) AR005658A1 (id)
AT (1) ATE330630T1 (id)
AU (1) AU706397B2 (id)
BR (1) BR9707049A (id)
CZ (1) CZ299452B6 (id)
DE (1) DE69736197T2 (id)
DK (1) DK1007089T3 (id)
ES (1) ES2267131T3 (id)
HU (1) HU225903B1 (id)
ID (1) ID17156A (id)
IL (1) IL125380A0 (id)
MA (1) MA24512A1 (id)
MX (1) MX9805810A (id)
NO (1) NO983284L (id)
NZ (2) NZ331014A (id)
PL (1) PL187274B1 (id)
PT (1) PT1007089E (id)
SI (1) SI1007089T1 (id)
TR (1) TR199801390T2 (id)
WO (1) WO1997026010A1 (id)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US20040038898A1 (en) * 1996-05-16 2004-02-26 The Trustees Of Columbia University Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
EP1001991A4 (en) * 1997-07-03 2005-01-26 Smithkline Beecham Corp CRYSTALLINE STRUCTURES OF FAB ANTI-FACTOR IX FRAGMENTS AND METHODS OF USE FOR PEPTIDOMIMETIC DESIGN
DE19802139C1 (de) * 1998-01-22 1999-09-23 Centeon Pharma Gmbh Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung
AU760678B2 (en) * 1998-05-08 2003-05-22 Stichting Sanquin Bloedvoorziening Method for diagnosis and treatment of haemophilia a patients with an inhibitor
US7250494B2 (en) 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
WO2000007626A1 (en) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
WO2000012562A1 (en) 1998-08-28 2000-03-09 Genentech, Inc. HUMAN ANTI-FACTOR IX/IXa ANTIBODIES
JP4803879B2 (ja) * 1998-10-31 2011-10-26 アメリカ合衆国 ヒト化抗−癌腫モノクローナル抗体ｃｃ４９
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US7829085B2 (en) 1999-07-14 2010-11-09 Life Sciences Research Partners Vzw Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
US7067313B1 (en) 1999-07-14 2006-06-27 D. Collen Research Foundation Ligands for use in therapeutic compositions for the treatment of hemostasis disorders
ES2283308T3 (es) * 1999-07-14 2007-11-01 D. Collen Research Foundation Vzw Anticuerpo monoclonal para el factor viii, que incluso cuando esta presente en exceso molar inactiva el factor viii solo en parte y metodo para producir dicho anticuerpo.
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
US6316259B1 (en) * 2000-01-21 2001-11-13 Isis Pharmaceuticals, Inc. Antisense inhibition of glycogen synthase kinase 3 alpha expression
WO2001087339A1 (en) * 2000-05-15 2001-11-22 Smithkline Beecham Corporation Antithrombotic agents
AU9630501A (en) * 2000-09-26 2002-04-08 Univ Duke Rna aptamers and methods for identifying the same
ATE468136T1 (de) 2001-01-11 2010-06-15 D Collen Res Foundation Vzw Verfahren und pharmazeutische zusammensetzung zur vorbeugung und/oder behandlung des syndroms der systemischen entzündlichen reaktion
WO2002076499A2 (en) * 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
AU2002313194B9 (en) * 2001-06-12 2008-06-05 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human-type anti-blood coagulation factor VIII antibody
JP2004536835A (ja) * 2001-07-09 2004-12-09 アフトン コーポレーション 肝臓、肺および食道の癌性ならびに前癌性状態の治療および防止
WO2003013423A2 (en) * 2001-08-05 2003-02-20 Gvg, Inc. Antithrombotic agent
US20040052779A1 (en) * 2001-12-21 2004-03-18 Stinson Jeffrey R. Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
EP1532162B1 (en) 2002-06-28 2013-08-07 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors
US6928528B1 (en) 2002-10-07 2005-08-09 Advanced Micro Devices, Inc. Guaranteed data synchronization
CA2520010C (en) * 2003-03-28 2012-07-10 Aphton Corporation Gastrin hormone immunoassays
JP4422430B2 (ja) 2003-05-14 2010-02-24 帝國製薬株式会社 エストロゲン及び／又はプロゲストゲン含有外用貼付剤
US7785594B2 (en) 2003-08-14 2010-08-31 Life Sciences Research Partners Vzw Factor VIII inhibitory antibodies with reduced glycosylation
US7589181B2 (en) 2003-08-29 2009-09-15 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use
US7297336B2 (en) 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
WO2005035753A1 (ja) * 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
US20080075712A1 (en) * 2003-10-14 2008-03-27 Kunihiro Hattori Double Specific Antibodies Substituting For Functional Proteins
JP5576592B2 (ja) * 2004-03-29 2014-08-20 キャンサー アドヴァンシズ インコーポレイテッド ガストリンホルモンに対するモノクローナル抗体
KR101333168B1 (ko) * 2004-09-22 2013-11-28 리셉터 바이오로직스 인크 프로가스트린에 대한 모노클로날 항체
TWI544076B (zh) 2005-03-31 2016-08-01 中外製藥股份有限公司 A method of manufacturing a polypeptide that controls assembly
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP2091564A4 (en) * 2006-10-16 2010-09-01 Novelmed Therapeutics Inc METHOD FOR THE AVOIDANCE OF ANTIBODIES TO THE HUMAN ANTIFACTOR VA AND THE USE THEREOF
WO2009033743A1 (en) * 2007-09-13 2009-03-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
CA2704064A1 (en) 2007-09-13 2009-03-29 University Of Zurich Humanized antibodies against the .beta.-amyloid peptide
RU2510400C9 (ru) 2007-09-26 2014-07-20 Чугаи Сейяку Кабусики Кайся Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr
WO2009049234A2 (en) * 2007-10-11 2009-04-16 Regents Of The University Of California Methods of treating coagulopathy
ES2702365T3 (es) * 2008-06-19 2019-02-28 Prothix Bv Uso de anticuerpos antifactor XI para la prevención o el tratamiento de la formación de trombos
KR101398290B1 (ko) 2010-11-17 2014-05-22 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
AU2013364043B2 (en) 2012-12-21 2018-01-04 Seagen Inc. Anti-NTB-A antibodies and related compositions and methods
US10442868B2 (en) 2013-03-14 2019-10-15 Rhode Island Hospital, A Lifespan-Partner Treating hepatitis B virus infections by administering receptor associated protein (RAP)
AU2014325063B2 (en) 2013-09-27 2019-10-31 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
EP3194437B1 (en) 2014-08-07 2021-01-20 Novartis AG Angiopoietin-like 4 (angptl4) antibodies and methods of use
BR112017002173B1 (pt) 2014-08-07 2023-11-21 Novartis Ag Anticorpo isolado anti-angptl4, ou fragmento de ligação ao antígeno do mesmo, seu uso, e composição farmacêutica
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
UY36751A (es) 2015-06-26 2017-01-31 Novartis Ag Anticuerpos de factor xi y métodos de uso
KR20250054123A (ko) * 2015-07-21 2025-04-22 다케다 파머수티컬 컴패니 리미티드 Xiia 인자의 단일클론 항체 저해제
US20200270363A1 (en) 2015-12-25 2020-08-27 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
AU2017209083A1 (en) 2016-01-22 2018-07-12 Adimab, Llc Anti-coagulation factor XI antibodies
CR20180554A (es) 2016-04-28 2019-01-10 Chugai Pharmaceutical Co Ltd Preparaciones que contienen anticuerpos
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
WO2017218371A1 (en) 2016-06-14 2017-12-21 Merck Sharp & Dohme Corp. Anti-coagulation factor xi antibodies
EP3492496A4 (en) 2016-07-29 2020-07-29 Chugai Seiyaku Kabushiki Kaisha BISPECIFIC ANTIBODIES PRESENTING AN INCREASED ALTERNATIVE FUNCTIONAL ACTIVITY OF COFACTOR FVIII
AU2017325240B9 (en) 2016-09-06 2025-02-13 Chugai Seiyaku Kabushiki Kaisha Methods of using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X
TN2019000164A1 (en) * 2016-11-23 2020-10-05 Bioverativ Therapeutics Inc Mono- and bispecific antibodies binding to coagulation factor ix and coagulation factor x
KR102918597B1 (ko) * 2016-12-23 2026-01-28 노파르티스 아게 항-인자 XI/XIa 항체를 사용한 치료 방법
WO2018116255A1 (en) 2016-12-23 2018-06-28 Novartis Ag Factor xi antibodies and methods of use
JP7469225B2 (ja) 2017-06-15 2024-04-16 キャンサー アドヴァンシーズ インク． 腫瘍及び癌に対する体液性及び細胞性免疫を誘発するための組成物及び方法
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
GB201709970D0 (en) * 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
CN111108202B (zh) 2017-09-29 2024-10-22 中外制药株式会社 具有凝血因子viii(fviii)辅因子功能替代活性的多特异性抗原结合分子及含有所述分子作为活性成分的药物制剂
CN119161488A (zh) 2017-11-01 2024-12-20 中外制药株式会社 具有降低的生物活性的抗体变体和同种型
US20220064327A1 (en) 2018-12-21 2022-03-03 Kymab Limited Fixaxfx bispecific antibody with common light chain
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3909799A1 (de) * 1989-03-24 1990-09-27 Behringwerke Ag Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2049655C (en) * 1990-09-17 1996-11-12 Akio Odawara Pharmaceutical composition for inhibiting platelet aggregation
WO1993009804A1 (en) * 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
US5383928A (en) * 1992-06-10 1995-01-24 Emory University Stent sheath for local drug delivery
WO1994005692A1 (en) * 1992-08-27 1994-03-17 Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Nederlandse Rode Kruis Antibodies specific for a haemostatic protein, their use for isolating intact protein, haemostatic compositions devoid of proteolytic cleavage products of the protein
US5397581A (en) * 1993-02-05 1995-03-14 Lerman; Russell E. Means for continuous confectionery coating of edible centers
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US20070190059A1 (en) * 1996-01-17 2007-08-16 Smithkline Beecham Corporation Antithrombotic agents

Also Published As

Publication number Publication date
US20070224198A1 (en) 2007-09-27
ATE330630T1 (de) 2006-07-15
HK1029513A1 (en) 2001-04-06
MX9805810A (es) 1998-11-30
TR199801390T2 (xx) 1998-12-21
CN1213312A (zh) 1999-04-07
DE69736197T2 (de) 2007-06-21
JP2007325602A (ja) 2007-12-20
DE69736197D1 (de) 2006-08-03
AR005658A1 (es) 1999-07-14
NZ501215A (en) 2001-04-27
HUP9900396A3 (en) 2001-10-29
NO983284D0 (no) 1998-07-16
HUP9900396A2 (hu) 1999-05-28
EP1832297A1 (en) 2007-09-12
PL187274B1 (pl) 2004-06-30
NZ331014A (en) 2000-01-28
DK1007089T3 (da) 2006-10-09
KR19990077329A (ko) 1999-10-25
KR100553629B1 (ko) 2006-10-04
WO1997026010A1 (en) 1997-07-24
EP1007089A4 (en) 2003-04-16
PL327929A1 (en) 1999-01-04
US20020146411A1 (en) 2002-10-10
MA24512A1 (fr) 1998-12-31
NO983284L (no) 1998-09-16
SI1007089T1 (sl) 2006-12-31
HU225903B1 (en) 2007-12-28
ES2267131T3 (es) 2007-03-01
US6005091A (en) 1999-12-21
EP1007089A1 (en) 2000-06-14
CZ299452B6 (cs) 2008-07-30
US6391299B1 (en) 2002-05-21
CZ222598A3 (cs) 2000-01-12
JP2000503210A (ja) 2000-03-21
PT1007089E (pt) 2006-11-30
US20070003553A1 (en) 2007-01-04
AU1830897A (en) 1997-08-11
BR9707049A (pt) 2000-10-24
IL125380A0 (en) 1999-03-12
AU706397B2 (en) 1999-06-17
EP1007089B1 (en) 2006-06-21

Similar Documents

Publication Publication Date Title
ID17156A (id) Zat-zat anti koagulan yang berguna dalam pengobatan trombosis
EE03512B1 (et) Epinastiin kasutamiseks valude ravis
HUP9904361A3 (en) Use of isobutylgaba and its derivatives for the treatment of pain
DE59500555D1 (de) Mittel zur Wasserbehandlung
ID15858A (id) Turunan triazol yang berguna dalam terapi
DE69630947D1 (de) Mittel zur schmerzbehandlung
FI963252L (fi) Kivun hoitoon tarkoitetut uudet opioidipeptidit ja niiden käyttö
FI970920L (fi) Trifenyylietyleenejä käytettäväksi osteoporoosin ehkäisyyn ja hoitoon
DE69524138D1 (de) Hautbehandlungsmittel
DE69825447D1 (de) Gerät zur dermatologischen behandlung
DE69830660D1 (de) Behandlung von atemstillstand im schlaf
DE69729817D1 (de) Behandlung von Aldehyd-fixierten Geweben
PT1017408E (pt) Utilizacao de tetra-hidrolipstatina no tratamento de diabetes de tipo ii
ID18679A (id) Penggunaan terapi lanjutan
ID21948A (id) Penggunaan 1-hidroksi-2piridon untuk pengobatan infeksi-infeksi kulit
DE59609662D1 (de) Haarbehandlungsmittel
FI951060A7 (fi) Formulaatioita ja hoitomenetelmiä
NO951825D0 (no) Vannbasert hårbehandlingspreparat og anvendelse av dette
DE69732024D1 (de) Haarbehandlungsmittel
FI963099L (fi) Vedenkäsittelymenetelmä ja -laite
PT932400E (pt) Derivados de anticonvulsionantes uteis no tratamento da dor neuropatica
GB9816234D0 (en) Compounds for use in the treatment of inflammation
DE69739850D1 (de) Anti-reflektierende Behandlung von reflektierenden Oberflächen
ID21874A (id) Penggunaan 1-hidroksi-2-piridon untuk pengobatan infeksi urap kulit
DE59708501D1 (de) Haarbehandlungsmittel